Compare Main Street Capital Corporation (MAIN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs TransMedics Group Inc — how do they compare? Main Street Capital Corporation trades at $58.43 (market cap $5.52B), while TransMedics Group Inc trades at $87.42 (market cap $3.10B). The key difference: Main Street Capital Corporation is the larger of the two by market cap, and Main Street Capital Corporation pays a 5.39% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MAIN | TMDX | |
|---|---|---|
Market Cap | $5.52B | $3.10B |
Sector | Financials | Technology |
52-Week High | $67.54 | $150.42 |
52-Week Low | $49.63 | $61.99 |
Dividend Yield | 5.39% | — |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAIN trades at $58.48, down slightly by 0.07% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q2 2026 EPS of $0.97, beating estimates, though Q1 was a miss. Revenue has grown from $318M in 2022 to $592M in 2025, with net income margins above 80%. Recent news highlights MAIN's dividend reliability amid sector challenges, with multiple dividends declared for 2026.
Outlook remains positive given strong profitability and dividend consistency, but risks include expense pressures and sector volatility. Analysts are mostly neutral with a consensus price target of $56.67, below the current price, suggesting limited near-term upside. The stock's high valuation multiples and overbought technicals warrant caution despite solid fundamentals.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
